Pharmaceutical

Biostax and Immgenuity to expedite HIV immunotherapies development

Biostax and Immgenuity have entered into an agreement to expedite the development of new immunotherapeutics to treat HIV and other diseases.

Aug 30, 2023 - 20:00
Biostax and Immgenuity to expedite HIV immunotherapies development
Biostax and Immgenuity have entered into an agreement to expedite the development of new immunotherapeutics to treat HIV and other diseases.
Read the original article

Tags:

Previous Article

FibroGen’s pamrevlumab disappointing results marks second failure in a row

Next Article

EC grants approval to Merck’s Keytruda for gastric cancer

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Pharmalittle: FDA approves first gene therapy for Duchenne muscular dystrophy; states join FTC to stop Amgen deal

STAT+: Pharmalittle: FDA approves first gene therapy fo...

Jun 24, 2023

STAT+: ITC recommends partial import ban of Apple Watches in Masimo patent case

STAT+: ITC recommends partial import ban of Apple Watch...

Oct 28, 2023

Bacterial infection may be ‘key event’ in common but mysterious endometriosis, study says

Bacterial infection may be ‘key event’ in common but my...

Jun 14, 2023